comparemela.com
  1. Home
  2. Live Updates
  3. Andromeda - Breaking News

Latest Breaking News On - Andromeda - Page 6 : comparemela.com

Auckland solo mum says homeschooling the best and most affordable option

Solo mum Andromeda Teuaki Ki Tangipa says choosing to homeschool her young daughter has helped them save money - and she is encouraging more Pasifika.

New zealandTodd roughtonMinistry of educationCity christian collegeAndromeda teuaki ki tangipaWest aucklandHome schooling new zealandAccredited christian educationWest city christianPacific island

Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

Vaishali Sanchorawala, MD, provides insights on the pooled safety analysis of data from phase 1 to 3 trials, including PRONTO and VITAL, which investigated the use of birtamimab in patients with light chain (AL) amyloidosis.

United statesVaishali sanchorawalaHeather landauJeffrey zonderPeer exchangeAmerican society of hematologyAmerican societyLight chain amyloidosisAl amyloidosisAffirm alNexicart 1Amyloid depositsCd 38 directed monoclonal antibodiesCardiac involvementMayo cardiac stagingStem cell transplant

The Potential Role of CAR T Therapy in AL Amyloidosis

A panel of expert oncologists discuss the underlying rationale and potential role for CAR T therapy in patients with AL amyloidosis.

Heather landauJeffrey zonderVaishali sanchorawalaPeer exchangeLight chain amyloidosisAl amyloidosisAffirm alNexicart 1Amyloid depositsCd 38 directed monoclonal antibodiesCardiac involvementMayo cardiac stagingStem cell transplantDuration of therapyUnmet needsManaging al amyloidosis

Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL

A panel of expert oncologists explore novel therapies using monoclonal antibodies designed to target amyloid deposit, highlighting key data from the VITAL study.

Transforming outcomesPrecision medicineTargeted therapiesTreatment approachesAbs targeting amyloid depositsLight chain amyloidosisAl amyloidosisAffirm alNexicart 1Amyloid depositsCd 38 directed monoclonal antibodiesCardiac involvementMayo cardiac stagingStem cell transplantDuration of therapyUnmet needs

AFFIRM-AL: Birtamimab in Patients with Mayo Stage IV AL Amyloidosis

A panel of expert oncologists explore the ongoing AFFIRM-AL trial, examining birtamimab in patients diagnosed with Mayo stage IV AL amyloidosis.

Transforming outcomesPrecision medicineTargeted therapiesMayo stageLight chain amyloidosisAl amyloidosisAffirm alNexicart 1Amyloid depositsCd 38 directed monoclonal antibodiesCardiac involvementMayo cardiac stagingStem cell transplantDuration of therapyUnmet needsManaging al amyloidosis

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.